3.74
0.00%
+0.00
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance
Yahoo Finance
Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug - Clinical Trials Arena
Clinical Trials Arena
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report? - Yahoo Canada Shine On
Yahoo Canada Shine On
Age-related Macular Degeneration Market to Exhibit Substantial Growth Rate - openPR
openPR
Age-related Macular Degeneration Market to Exhibit Substantial Growth Rate | Regeneron Pharmaceuticals, Novartis ... - Barchart
Barchart
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including ... - Investing.com India
Investing.com India
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully - Simply Wall St
Simply Wall St
The Kodiak Sciences Inc (KOD) had a good session last reading, didn't it? – US Post News - US Post News
US Post News
Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely? - Yahoo Finance
Yahoo Finance
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Zacks Investment Research
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
Zacks Investment Research
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
Zacks Investment Research
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus - Zacks Investment Research
Zacks Investment Research
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
US Stocks Flat; Initial Jobless Claims Fall To 210,000
Benzinga
Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results - GuruFocus.com
GuruFocus.com
Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
Zacks Investment Research
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
Zacks Investment Research
Kodiak Sciences patent describes NLRP3 inflammasome inhibitors - BioWorld Online
BioWorld Online
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
Zacks Investment Research
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
Zacks Investment Research
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
Zacks Investment Research
Oxurion to file for bankruptcy following trial failure - Clinical Trials Arena
Clinical Trials Arena
Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ... - Yahoo Finance
Yahoo Finance
KOD Stock Quote Price and Forecast - CNN
CNN
Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the ... - GlobeNewswire
GlobeNewswire
Kodiak's shelved tarcocimab succeeds in RVO trial - Clinical Trials Arena
Clinical Trials Arena
Age-Related Macular Degeneration Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies - Opthea ... - GlobeNewswire
GlobeNewswire
Kodiak CMO Steps Down After Phase III Flops for Eye Therapy - BioSpace
BioSpace
Kodiak Sciences Inc. (NASDAQ:KOD) Is Expected To Breakeven In The Near Future - Yahoo Finance
Yahoo Finance
Why Is Kodiak Sciences (KOD) Stock Down 58% Today? - InvestorPlace
InvestorPlace
Kodiak Sciences begins subject treatment in DME therapy trial - Clinical Trials Arena
Clinical Trials Arena
Nanoscope Therapeutics announces WHO selection of 'sonpiretigene isteparvovec' as international nonproprietary ... - Modern Retina
Modern Retina
Kodiak: Turnaround Strategy Has Shown Life Thus Far (NASDAQ:KOD) - Seeking Alpha
Seeking Alpha
Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight - GlobeNewswire
GlobeNewswire
Kodiak Sciences Stock: The Busted Biotech World (NASDAQ:KOD) - Seeking Alpha
Seeking Alpha
Kodiak Sciences Stock: Expecting Sentiment To Turn Bullish - Seeking Alpha
Seeking Alpha
Why Kodiak Sciences Stock Is Sharply Lower Today - The Motley Fool
The Motley Fool
Lonza and Kodiak open custom-built bioconjugation facility - European Pharmaceutical Review
European Pharmaceutical Review
Kodiak Sciences rises after director Baker Bros Advisors buys shares worth ~$4.4M - Seeking Alpha
Seeking Alpha
Grand Opening Of Kodiak Sciences’ Bioconjugation Facility - Contract Pharma
Contract Pharma
Kodiak Sciences Stock: Potential For Comeback After Trial Setback (NASDAQ:KOD) - Seeking Alpha
Seeking Alpha
KSI-301 Disappoints (NASDAQ:KOD) - Seeking Alpha
Seeking Alpha
Peninsula biotech stock loses 80% after eye drug's late-stage study fails - San Francisco Business Times - The Business Journals
The Business Journals
Surgeon completes first successful implantation of wireless visual prosthesis brain implant - Ophthalmology Times
Ophthalmology Times
Palo Alto's Kodiak Sciences just turned down a $125M investment. Here's why. - Silicon Valley Business Journal - The Business Journals
The Business Journals
자본화:
|
볼륨(24시간):